Cidara Therapeutics, Inc.

Contributing Author

Recent Articles by Cidara Therapeutics, Inc.

Oct-23	Cidara Therapeutics to Report Third Quarter 2025 Financial Results and Host Quarterly Conference Call on November 6, 2025 CDTX GlobeNewswire
Oct-23	Cidara Therapeutics Announces Late-Breaking Presentation on CD388 at 10ᵗʰ ESWI Influenza Conference 2025 CDTX GlobeNewswire
Oct-21	Cidara Therapeutics Announces Late-Breaking Phase 2b Data Presentation on CD388 at ID Week 2025 CDTX GlobeNewswire
Oct-13	Cidara Therapeutics to Present Late-Breaking Clinical Phase 2 Data on CD388 at ID Week 2025 CDTX GlobeNewswire
Oct-10	Cidara Therapeutics to Present at 10th ESWI Influenza Conference 2025 CDTX GlobeNewswire
Oct-09	Cidara Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for CD388 in Seasonal Influenza Prevention CDTX GlobeNewswire
Oct-02	Cidara Therapeutics Announces BARDA Award to Support Expanded Manufacturing and Clinical Development of CD388, its Non-Vaccine Influenza Preventative Therapeutic CDTX GlobeNewswire
Sep-25	Cidara Therapeutics Announces First Participants Dosed in Phase 3 ANCHOR Trial Evaluating CD388 for the Prevention of Seasonal Influenza in High-Risk Populations CDTX GlobeNewswire
Sep-24	Cidara Therapeutics Announces Expanded and Accelerated Phase 3 Plan for CD388, a Non-Vaccine Preventative of Seasonal Influenza CDTX GlobeNewswire
Sep-17	Cidara Therapeutics Presents Data on CD388 from its Phase 2b NAVIGATE Trial and Preclinical Studies Against H5N1 at ISRV's 8th AVG and 3rd IMRP 2025 Meeting CDTX GlobeNewswire
Sep-04	Cidara Therapeutics to Participate in September Investor Conferences CDTX GlobeNewswire
Sep-03	Cidara Therapeutics to Present Clinical Phase 2b Data and Preclinical H5N1 Data on CD388 at ISRV's 8th AVG and 3rd IMRP 2025 Meeting CDTX GlobeNewswire
Aug-07	Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results CDTX GlobeNewswire
Jul-24	Cidara Therapeutics to Report Second Quarter 2025 Financial Results and Host Quarterly Conference Call on August 7, 2025 CDTX GlobeNewswire
Jul-01	Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) CDTX GlobeNewswire
Jun-30	Cidara Therapeutics Announces Inclusion in the Russell 2000 and Russell 3000 Indexes CDTX GlobeNewswire
Jun-26	Cidara Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares CDTX GlobeNewswire
Jun-24	Cidara Announces Pricing of Upsized Public Offering of Common Stock CDTX GlobeNewswire
Jun-23	Cidara Announces Proposed Public Offering of Common Stock CDTX GlobeNewswire
Jun-23	Cidara Therapeutics Announces Positive Topline Results from its Phase 2b NAVIGATE Trial Evaluating CD388, a Non-Vaccine Preventative of Seasonal Influenza CDTX GlobeNewswire
May-15	Cidara Therapeutics to Host Virtual R&D Day to Discuss CD388 as a Potential Universal, Once-Per-Flu Season Preventative of Seasonal and Pandemic Influenza on May 22, 2025 CDTX GlobeNewswire
May-13	Cidara Therapeutics to Participate in Two Upcoming Investor Conferences CDTX GlobeNewswire
May-08	Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results CDTX GlobeNewswire
May-01	Cidara Therapeutics Announces Promotion of Nicole Davarpanah to Chief Medical Officer and Corrina Pavetto to SVP, Clinical Development CDTX GlobeNewswire

Cidara Therapeutics, Inc.

Recent Articles by Cidara Therapeutics, Inc.

Upgrade your FINVIZ experience